JP2021505568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505568A5 JP2021505568A5 JP2020530502A JP2020530502A JP2021505568A5 JP 2021505568 A5 JP2021505568 A5 JP 2021505568A5 JP 2020530502 A JP2020530502 A JP 2020530502A JP 2020530502 A JP2020530502 A JP 2020530502A JP 2021505568 A5 JP2021505568 A5 JP 2021505568A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- hydrogen
- membered
- optionally
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1 -C 3 alkoxy Chemical group 0.000 claims 95
- 229910052739 hydrogen Inorganic materials 0.000 claims 42
- 239000001257 hydrogen Substances 0.000 claims 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 23
- 125000001424 substituent group Chemical group 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000001153 fluoro group Chemical group F* 0.000 claims 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 2
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims 2
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000001668 ameliorated effect Effects 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- GSJJVNAPLSISFR-CQSZACIVSA-N (6S)-1-benzyl-6-(3,5-difluorophenyl)-2,5,6,7-tetrahydropyrrolo[1,2-c]imidazole-3-thione Chemical compound C(C1=CC=CC=C1)C1=C2N(C(N1)=S)C[C@@H](C2)C1=CC(=CC(=C1)F)F GSJJVNAPLSISFR-CQSZACIVSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1720189.8 | 2017-12-04 | ||
| GBGB1720189.8A GB201720189D0 (en) | 2017-12-04 | 2017-12-04 | Dopamine-B-hydroxylase inhibitors |
| GB1804439.6 | 2018-03-20 | ||
| GBGB1804439.6A GB201804439D0 (en) | 2018-03-20 | 2018-03-20 | Dopamin-b-hydroxylase inhibitors |
| PCT/PT2018/050043 WO2019112457A1 (en) | 2017-12-04 | 2018-11-30 | Dopamine-β-hydroxylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505568A JP2021505568A (ja) | 2021-02-18 |
| JP2021505568A5 true JP2021505568A5 (https=) | 2022-01-11 |
| JP7167155B2 JP7167155B2 (ja) | 2022-11-08 |
Family
ID=65012066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530502A Active JP7167155B2 (ja) | 2017-12-04 | 2018-11-30 | ドーパミン-β-ヒドロキシラーゼ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11434242B2 (https=) |
| EP (1) | EP3720856A1 (https=) |
| JP (1) | JP7167155B2 (https=) |
| KR (1) | KR20200096584A (https=) |
| CN (1) | CN111479812A (https=) |
| AU (1) | AU2018379646A1 (https=) |
| BR (1) | BR112020010216A2 (https=) |
| CA (1) | CA3082337A1 (https=) |
| CL (1) | CL2020001461A1 (https=) |
| IL (1) | IL274550B2 (https=) |
| MX (1) | MX2020005864A (https=) |
| PH (1) | PH12020500542A1 (https=) |
| RU (1) | RU2020121820A (https=) |
| SG (1) | SG11202004231YA (https=) |
| TW (1) | TW201925193A (https=) |
| WO (1) | WO2019112457A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111479812A (zh) | 2017-12-04 | 2020-07-31 | 巴尔-波特拉及康邦亚股份有限公司 | 多巴胺-b-羟化酶抑制剂 |
| GB201908044D0 (en) | 2019-06-05 | 2019-07-17 | Bial Portela & Ca Sa | Dopamine-B-Hydroxylase inhibitors |
| US20250122171A1 (en) * | 2023-09-20 | 2025-04-17 | Deep Apple Therapeutics, Inc. | Substituted Amine Compounds, Compositions and Methods of Use |
| CN120383599A (zh) * | 2024-01-29 | 2025-07-29 | 上海深势唯思科技有限责任公司 | 芳基杂环类Kv1.3抑制剂及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647790A (en) | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
| FR2449689A1 (fr) | 1979-02-20 | 1980-09-19 | Logeais Labor Jacques | Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique |
| US4628059A (en) | 1985-10-31 | 1986-12-09 | Smithklein Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
| WO1995029165A2 (en) | 1994-04-26 | 1995-11-02 | Syntex (U.S.A.) Inc. | Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors |
| US6482982B1 (en) | 2001-03-09 | 2002-11-19 | University Of Sciences Of Philadelphia | Halogenated antituberculosis agents |
| IL143379A (en) * | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
| US7125904B2 (en) | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| WO2008085008A1 (en) | 2007-01-11 | 2008-07-17 | Mogam Biotechnology Research Institute | T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases |
| GB0708818D0 (en) * | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| JP2010534676A (ja) | 2007-07-23 | 2010-11-11 | シノシア・セラピューティクス | 心的外傷後ストレス障害の治療 |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
| CN111479812A (zh) | 2017-12-04 | 2020-07-31 | 巴尔-波特拉及康邦亚股份有限公司 | 多巴胺-b-羟化酶抑制剂 |
-
2018
- 2018-11-30 CN CN201880080871.5A patent/CN111479812A/zh active Pending
- 2018-11-30 SG SG11202004231YA patent/SG11202004231YA/en unknown
- 2018-11-30 CA CA3082337A patent/CA3082337A1/en active Pending
- 2018-11-30 KR KR1020207019157A patent/KR20200096584A/ko not_active Withdrawn
- 2018-11-30 RU RU2020121820A patent/RU2020121820A/ru unknown
- 2018-11-30 BR BR112020010216-4A patent/BR112020010216A2/pt not_active IP Right Cessation
- 2018-11-30 WO PCT/PT2018/050043 patent/WO2019112457A1/en not_active Ceased
- 2018-11-30 EP EP18833340.5A patent/EP3720856A1/en not_active Withdrawn
- 2018-11-30 MX MX2020005864A patent/MX2020005864A/es unknown
- 2018-11-30 TW TW107143059A patent/TW201925193A/zh unknown
- 2018-11-30 JP JP2020530502A patent/JP7167155B2/ja active Active
- 2018-11-30 AU AU2018379646A patent/AU2018379646A1/en not_active Abandoned
- 2018-11-30 US US16/769,045 patent/US11434242B2/en active Active
-
2020
- 2020-05-10 IL IL274550A patent/IL274550B2/en unknown
- 2020-06-01 CL CL2020001461A patent/CL2020001461A1/es unknown
- 2020-06-02 PH PH12020500542A patent/PH12020500542A1/en unknown
-
2022
- 2022-09-01 US US17/901,007 patent/US20230138795A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505568A5 (https=) | ||
| HRP20201641T1 (hr) | Novi spojevi i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja | |
| ES2629414T3 (es) | Derivados de tiazol | |
| JP2016523911A5 (https=) | ||
| JP2023071767A (ja) | Brm標的化化合物および関連使用方法 | |
| ES2901197T3 (es) | Moduladores alostéricos de los receptores nicotínicos de la acetilcolina | |
| JP2009529047A5 (https=) | ||
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| CA2831966C (en) | Thiazole derivatives | |
| RU2665036C2 (ru) | Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| HRP20200781T1 (hr) | DERIVATI PIRAZOLO[1,5-a]PIRAZIN-4-ILA KAO INHIBITORI JAK | |
| MX2008013400A (es) | Derivado de azolcarboxamida. | |
| JP2018501315A5 (https=) | ||
| IL274550B2 (en) | Dopamine-b-hydroxylase inhibitors | |
| JP2017531039A5 (https=) | ||
| AU2012342891B2 (en) | 3-Cyanoaryl-1H-pyrrolo[2.3-b]pyridine derivatives | |
| JP2013519724A5 (https=) | ||
| JP2015514783A (ja) | ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用 | |
| HRP20121069T1 (hr) | Supstituirani derivati amida kao inhibitori protein kinaze | |
| HRP20170295T1 (hr) | Oblik soli inhibitora ljudske histonske metiltransferaze ezh2 | |
| RU2012126083A (ru) | Производные аминооксазина | |
| JP2009515814A5 (https=) | ||
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| JP2016503785A5 (https=) |